Matias interviews Rob Malenka, Chief Scientific Officer of Bayshore, the family office of Google co-founder Sergey Brin.  Bayshore has played a major role in advancing treatments for Parkinson's, bipolar, and autism.

In this episode, we discuss:

• Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
• The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
• How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
• How success depends on mission-driven, ethical people who align science, capital, and patient impact.
• The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Brendon Boot of Skin2Neuron. Brendon is a neurologist at Harvard and Mayo Clinic with prior experience as Medical Director at Biogen overseeing their Phase 1b Alzheimer’s trials.

In this episode, we discuss:

• How skin-derived cells can be turned into neurons to repair the brain.
• Why replacing lost neurons may succeed where drugs have failed in Alzheimer’s.
• What makes autologous (self-derived) cell therapy safer and more effective.
• How testing in dogs brought stronger proof than traditional mouse models.
• Why this approach could shift Alzheimer’s treatment from slowing decline to restoring memory.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Natalie Yivgi-Ohana of Minovia. Natalie is a life science entrepreneur with twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010.

In this episode, we discuss:

• How mitochondria impacts health by not just regulating energy, but also hormones, cell survival, and overall cellular function
• Why mitochondrial dysfunction is a root cause of many conditions, from rare genetic disorders to aging and mental health issues.
• What mitochondrial therapy does by restoring function and improving cellular health
• What makes mitochondrial therapies distinct from gene therapies
• How to scale mitochondrial therapies for clinical adoption

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank